EUCTR2016-004573-40-IT进行中（未招募）1 期
Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics andpharmacogenomics of multiple intravenous doses of BI 655130 in patients with Palmoplantar Pustulosis (PPP) -
BOEHRINGER-INGELHEIM ITALIA S.P.A.0 个研究点目标入组 79 人开始时间: 2020年11月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 79
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients, 18 to 65 years of age at screening.
- •- Palmoplantar Pustulosis
- •- Further criteria apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Patients with associated plaque psoriasis = 10% of the body surface
- •- Presence or known history of anti-TNF-induced PPP-like disease.
- •- Active or latent tuberculosis
- •- Further criteria apply
研究者
相似试验
进行中（未招募）
1 期
A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease Palmoplantar PustulosisMedDRA version: 20.0Level: LLTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 100000004858Palmoplantar PustulosisEUCTR2018-003078-28-FRBoehringer Ingelheim France140
进行中（未招募）
1 期
A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease Palmoplantar PustulosisPalmoplantar PustulosisEUCTR2018-003078-28-GBBoehringer Ingelheim Limited140
已完成
2 期
Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP)Palmoplantar Pustulosis10014982NL-OMON48187Boehringer Ingelheim4
进行中（未招募）
1 期
A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease Palmoplantar PustulosisPalmoplantar PustulosisEUCTR2018-003078-28-PLBoehringer Ingelheim RCV GmbH & Co. KG140
进行中（未招募）
1 期
A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease Palmoplantar PustulosisPalmoplantar PustulosisMedDRA version: 21.1Level: PTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003078-28-BESCS Boehringer Ingelheim Comm.V140